Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinom, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mylan s.a.s., 117 allee des parcs, saint priest, francuska - aripiprazolum - tableta - 10 mg - urbroj: jedna tableta sadrži 10 mg aripiprazola

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mylan s.a.s., 117 allee des parcs, saint priest, francuska - aripiprazolum - tableta - 15 mg - urbroj: svaka tableta sadrži 15 mg aripiprazola

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mylan s.a.s., 117 allee des parcs, saint priest, francuska - aripiprazolum - tableta - 30 mg - urbroj: jedna tableta sadrži 30 mg aripiprazola

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novo nordisk a/s, novo alle, bagsvaerd, danska - glukagonklorid - prašak i otapalo za otopinu za injekciju - 1 mg - urbroj: jedna bočica sadrži 1 mg glukagona u obliku klorida, što odgovara 1 mg (1 iu) glukagona/ml nakon rekonstitucije

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alk-abelló a/s, boge allé 6-8, horsholm, danska - standardizirani ekstrakt alergena peludi bijele breze - sublingvalni liofilizat - 12 sq-bet - urbroj: jedan sublingvalni liofilizat sadrži 12 sq-bet standardiziranog alergena ekstrakta peludi bijele breze (betula verrucosa)

Europska Unija - hrvatski - EMA (European Medicines Agency)

orphelia pharma sas - clofarabine - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - liječenje akutne limfoblastične leukemije (all) u pedijatrijskih bolesnika koji imaju relapsed ili su vatrostalne nakon najmanje dva prethodnog režima i gdje nema drugih mogućnost liječenja predviđa da će rezultirati trajan odgovor. sigurnost i učinkovitost procijenjeni su u ispitivanjima bolesnika ≤ 21 godina kod početne dijagnoze.

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

bela-pharm gmbh & co. kg, lohner str. 19, 49377 vechta, njemačka - retinil palmitat (vit. a); all-rac-alfa-tokoferol acetat (vit. e); uljna otopina kolekalciferola (vit. d3) - otopina za injekciju - vitamini i minerali - goveda, konja, svinja, pasa

Europska Unija - hrvatski - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastična sredstva - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.